Recommended dose for Phase 2 studies Baseline to study completion [clinicaltrials_resource:b2b405c3c702902f958ca6234d3b9d6e]
Supplied as 25 mg and 100 mg capsules, administered orally for two 28-day cycles.
Starting dose is 50mg. Dose will be subsequently increased to 100mg, 200mg, and 300mg.
clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]
Recommended dose for Phase 2 studies Baseline to study completion [clinicaltrials_resource:b2b405c3c702902f958ca6234d3b9d6e]
Supplied as 25 mg and 100 mg capsules, administered orally for two 28-day cycles.
Starting dose is 50mg. Dose will be subsequently increased to 100mg, 200mg, and 300mg.
Bio2RDF identifier
b2b405c3c702902f958ca6234d3b9d6e
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:b2b405c3c702902f958ca6234d3b9d6e
measure [clinicaltrials_vocabulary:measure]
Recommended dose for Phase 2 studies
time frame [clinicaltrials_vocabulary:time-frame]
Baseline to study completion
description
Supplied as 25 mg and 100 mg c ...... ed to 100mg, 200mg, and 300mg.
identifier
clinicaltrials_resource:b2b405c3c702902f958ca6234d3b9d6e
title
Recommended dose for Phase 2 studies Baseline to study completion
@en
type
label
Recommended dose for Phase 2 s ...... 405c3c702902f958ca6234d3b9d6e]
@en